<DOC>
	<DOCNO>NCT00239759</DOCNO>
	<brief_summary>The goal MIRAGE evaluate association genetic non-genetic risk factor Alzheimer 's Disease .</brief_summary>
	<brief_title>MIRAGE : Multi-Institutional Research Alzheimer 's Genetic Epidemiology</brief_title>
	<detailed_description>For past 13 year MIRAGE project demonstrate genetic factor play major role development Alzheimer 's Disease ( AD ) among patient ascertain clinical setting . This research also show E4 variant apolipoprotein E ( APOE ) , strong AD risk factor identify thus far . The researcher turn attention grow body evidence pathological , epidemiological genetic study risk factor vascular disease also enhance risk AD . However , since epidemiological study lack neuroimaging data , unclear whether apparent association vascular risk factor AD bring ischemic injury brain , acceleration primary Alzheimer neurodegenerative process , process . Some vascular risk factor prevalent African American Japanese American population Caucasians . This study build upon early work evaluate association APOE , gene involve vascular function , indictors cerebrovascular health include blood pressure structural brain imaging ( MRI ) , susceptibility AD ethnic group . In order carry project successfully , sample 1000 patient ( 500 Caucasians , 300 African Americans , 200 Japanese Americans ) meet NINCDS/ADRDA criterion probable definite AD 11 center U.S. , Canada Germany recruit . Many patient identify exist family registry . Family history , medical history , epidemiological information obtain AD patient first-degree relative use standardized questionnaire instrument establish protocol . A cognitive screening test administer blood sample collect patient 's living sibling , spouse child age 50 year . DNA , plasma MRI brain evaluate patient sibling .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>NOTE : This trial accept patient Probable AD , cognitively normal brother sister Probable definite AD NINCDSADRDA criterion Living sibling cognitively normal measure brief standardized cognitive assessment Ages 60 Alzheimer 's disease patient Ages 50 cognitively normal sibling Early onset Alzheimer 's disease attribute APP , PS1 PS2 gene mutation History clinical stroke Siblings whose cognitive assessment meet study criterion Pacemaker contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Epidemiological study</keyword>
</DOC>